The outlook revision is based on a number of factors, including Moody’s Investors Service’s expectation that Skagit will maintain modest operating performance in 2017.
Moody’s also assigned a “Baa2” rating to Skagit’s $61.1 million of series 2016 bonds and affirmed the “Baa2” rating on $100 million of outstanding revenue bond debt.
The rating assignment and affirmation reflect Skagit’s strong market share in its primary service area and the rapid growth it has achieved over the past several years.
More articles on healthcare finance:
Smart Source partners with Convergent Revenue Cycle Management: 3 things to know
Fitch affirms Eisenhower Medical Center’s ‘BBB’ rating
S&P assigns ‘A+’ rating to RWJBarnabas Health’s bonds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
